Al-Ola A Abdallah: Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma
Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center, shared a post on X:
“ASH Abstracts:
Smoldering Myeloma.
1027 Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma.
- 6 pts were enrolled/Cilta-Cel to treat High risk smoldering myeloma.
- Efficacy:100% overall response rate, 50% CR.”
Authors: Omar Nadeem, Sarah Nikiforow, Kevin DeBraganca, Anna Bosch-Vilaseca, Elizabeth K. O’Donnell, Adam S. Sperling, Yuxin Liu, Frances Arters, Marjorie Marto, Colin O’Donnell, Brendan Kineavy, Sarah Holmes, Hope Wei, Emily Durlacher, Elizabeth Grimm, Amy Goguen, Rocio Montes de Oca, Lorenzo Trippa, Eric L. Smith, Kenneth C. Anderson, Nikhil C. Munshi, Mark Wildgust, Jerome Ritz, Craig Tendler, Irene Ghobrial.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023